This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
by Kinjel Shah
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
Wall Street Analysts Predict a 149.52% Upside in Fusion Pharmaceuticals Inc. (FUSN): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 149.5% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Fusion Pharmaceuticals Inc. (FUSN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Fusion Pharmaceuticals Inc. (FUSN) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in Fusion Pharmaceuticals Inc. (FUSN)? Wall Street Analysts Think 162%
by Zacks Equity Research
The mean of analysts' price targets for Fusion Pharmaceuticals Inc. (FUSN) points to a 162% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 37.50% and 389.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 2.56% and 88.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fusion (FUSN) to Begin Clinical Study on Targeted Alpha Therapy
by Zacks Equity Research
Fusion (FUSN) surges after investigational new drug application clearance by the FDA for its targeted alpha therapy FPI-2068, co-developed with AstraZeneca.
Fusion Pharmaceuticals Inc. (FUSN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 3.51% and 16.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 30.77% and 0.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
5 Stocks to Bet on in an Innovation-Driven Drug Industry
by Kinjel Shah
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US
by Zacks Equity Research
The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.
What Makes Fusion Pharmaceuticals Inc. (FUSN) a New Strong Buy Stock
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Pacira (PCRX) Up on Data From Exparel Label Expansion Study
by Zacks Equity Research
Pacira (PCRX) reports encouraging top-line data from the phase III study evaluating Exparel as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty. Shares rise.
After Plunging 14.9% in 4 Weeks, Here's Why the Trend Might Reverse for Fusion Pharmaceuticals Inc. (FUSN)
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Fusion Pharmaceuticals Inc. (FUSN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fusion Pharmaceuticals (FUSN) Jumps: Stock Rises 9%
by Zacks Equity Research
Fusion Pharmaceuticals (FUSN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.